Current Status and Future Prospects for the Genomic Diagnosis of Lung Cancer Using Cytological Samples

DOI Web Site 17 References
  • Morikawa Kei
    Division of Respiratory Diseases, Department of Internal Medicine, St. Marianna University School of Medicine

Bibliographic Information

Other Title
  • 細胞検体による肺癌ゲノム診断の現状と今後の展望

Search this article

Abstract

<p>With the spread of personalized medicine for non-small cell lung cancer, the importance of genetic panel screening at the time of the diagnosis is increasing. On the other hand, we often experienced cases in which sufficient amounts of tissue samples could not be collected, and the development of an alternative diagnostic method is required. The lung cancer compact panel™, which received approval from Pharmaceutical Affairs in November 2022 as the third multi-gene panel test in Japan, resulted in a high genetic analysis success rate, even for cytological samples. This new next generation sequencing panel test, which was released in February 2023, shows high accuracy and versatility. After confirming the presence of malignant cells in paired samples, fluid specimens such as pleural and pericardial effusions, as well as cytological brushing solution and needle wash can be submitted. In addition to the conventional procedures based on tissue specimens, standardization of the handling of cytological samples for genetic analyses is required. The use of cytological samples will increase the opportunities to submit gene panel tests for genetic mutation searches, thereby enhancing the spread of personalized treatment.</p>

Journal

  • Haigan

    Haigan 63 (3), 153-160, 2023-06-20

    The Japan Lung Cancer Society

References(17)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top